IDYA - Ideaya Biosciences Inc Stock Price, Fair Value and News

$34.34+0.65 (+1.93%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

IDYA Price Action

Last 7 days

-4.3%

Last 30 days

9.5%

Last 90 days

33.0%

Trailing 12 Months

28.8%

IDYA RSI Chart

IDYA Valuation

Market Cap

3.0B

Price/Earnings (Trailing)

-18.73

Price/Sales (Trailing)

114.34

Price/Free Cashflow

-28.56

IDYA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

IDYA Fundamentals

IDYA Revenue

Revenue (TTM)

23.4M

Rev. Growth (Yr)

189.09%

Rev. Growth (Qtr)

48.6%

IDYA Earnings

Earnings (TTM)

-160.7M

Earnings Growth (Yr)

330.11%

Earnings Growth (Qtr)

253.88%

IDYA Profitability

Return on Equity

-14.72%

Return on Assets

-13.56%

Free Cashflow Yield

-3.5%

IDYA Investor Care

Shares Dilution (1Y)

1.43%

Diluted EPS (TTM)

-1.92

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	0	0	0
2024	0	0	0	0
2023	47.5M	45.1M	23.5M	23.4M
2022	32.1M	29.1M	49.9M	50.9M
2021	21.6M	23.7M	25.8M	27.9M
2020	0	0	0	19.5M

Get all data in R, Python etc through our Historical Stock Data APIs

About Ideaya Biosciences Inc

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase II clinical trial for patients with solid tumors having methylthioadenosine phosphorylase gene deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester todevelop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase II/III study in metastatic uveal melanoma, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

CEO	Mr. Yujiro S. Hata
WEBSITE	ideayabio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	116

Ideaya Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Ideaya Biosciences Inc? What does IDYA stand for in stocks?

IDYA is the stock ticker symbol of Ideaya Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ideaya Biosciences Inc (IDYA)?

As of Wed Dec 03 2025, market cap of Ideaya Biosciences Inc is 3.01 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IDYA stock?

You can check IDYA's fair value in chart for subscribers.

Is Ideaya Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether IDYA is over valued or under valued. Whether Ideaya Biosciences Inc is cheap or expensive depends on the assumptions which impact Ideaya Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IDYA.

What is Ideaya Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, IDYA's PE ratio (Price to Earnings) is -18.73 and Price to Sales (PS) ratio is 114.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IDYA PE ratio will change depending on the future growth rate expectations of investors.